Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.67 |
| ▸ | JAK3 | P52333 | 10/20 | 0.66 |
| ▸ | EGFR | P00533 | 8/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | JAK1 | P23458 | 1/20 | 0.60 |
| ▸ | TTK | P33981 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | TXK | P42681 | 1/20 | 0.60 |
| ▸ | BLK | P51451 | 1/20 | 0.60 |
| ▸ | ITK | Q08881 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17856988 | 0.90 | EGFR (0.66) | BTKJAK3EGFRJAK2JAK1 | |
| SCHEMBL16371894 | 0.90 | EGFR (0.71) | BTKJAK3EGFRJAK2JAK1 | |
| SCHEMBL17856994 | 0.88 | BTK (0.64) | BTKJAK3EGFRJAK2JAK1 | |
| SCHEMBL17857114 | 0.85 | EGFR (0.52) | BTKJAK3EGFR | |
| SCHEMBL17857071 | 0.84 | EGFR (0.66) | BTKJAK3EGFR | |
| SCHEMBL17857072 | 0.81 | BTK (1.00) | BTKJAK3EGFRJAK2JAK1 | |
| SCHEMBL19441915 | 0.80 | EGFR (0.51) | JAK3EGFR | |
| SCHEMBL17209827 | 0.80 | JAK3 (1.00) | BTKJAK3EGFRJAK2JAK1 | |
| SCHEMBL18411389 | 0.79 | BTK (0.77) | BTKJAK3EGFRITK | |
| SCHEMBL23243691 | 0.78 | CTSC (0.65) | BTKJAK3EGFRJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906878-B2 | Kinase inhibitors for the treatment of disease | DANA FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190256475-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10316002-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170369449-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256475-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | BTK 4/4885JAK3 18/4885EGFR 24/4885 |
| US-20170369449-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | BTK 4/4885JAK3 18/4885EGFR 24/4885 |
| US-10906878-B2 | Kinase inhibitors for the treatment of disease | BLK, ROS1, TEC | BTK 4/4885JAK3 18/4885EGFR 24/4885 |
| US-10316002-B2 | Kinase inhibitors for the treatment of disease | BLK, ROS1, TEC | BTK 4/4885JAK3 18/4885EGFR 24/4885 |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | BTK 4/4885JAK3 18/4885EGFR 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.